Texas Childrens Hospital
Welcome,         Profile    Billing    Logout  
 86 Trials 
53 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Dubois, Steven
SARC037, NCT04067115: a Phase I/II Study to Evaluate the Safety of Trabectedin in Combination with Irinotecan in Ewing Sarcoma Patients

Active, not recruiting
1/2
48
US
Trabectedin 1 MG [Yondelis], Irinotecan, tumor biopsy, 3'-Deoxy-3'-18F Fluorothymidine (18F-FLT) Imaging, 18F-FLT Imaging
Sarcoma Alliance for Research through Collaboration, Janssen Scientific Affairs, LLC, National Institutes of Health (NIH), National Cancer Institute (NCI)
Ewing Sarcoma
06/25
06/25
LIBRETTO-121, NCT03899792 / 2019-000212-28: A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Recruiting
1/2
50
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma
12/24
05/29
LiFFT, NCT05918640: Lurbinectedin in FET-Fused Tumors

Recruiting
1/2
56
US
Lurbinectedin
Children's Hospital of Philadelphia, Jazz Pharmaceuticals, Stand Up To Cancer
Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
07/26
07/28
CARE study, NCT04094610 / 2019-003055-11: A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations

Checkmark Initial data from P1/2 CARE trial for pediatric and young adult patients with solid tumors at SIOP 2021
Oct 2021 - Oct 2021: Initial data from P1/2 CARE trial for pediatric and young adult patients with solid tumors at SIOP 2021
Recruiting
1/2
75
Europe, Canada, US, RoW
Oral repotrectinib (TPX-0005), Oral repotrectinib (TPX-0005) capsules, Oral repotrectinib (TPX-0005) oral suspension, repotrectinib
Turning Point Therapeutics, Inc., Turning Point Therapeutics, Inc. (a wholly owned subsidiary of Bristol Myers Squibb Company)
Locally Advanced Solid Tumors, Metastatic Solid Tumors, Lymphoma, Primary CNS Tumors
09/26
09/27
NCT05429502 / 2021-005617-14: Study of Efficacy and Safety of Ribociclib (LEE011) in Combination With Topotecan and Temozolomide (TOTEM) in Pediatric Patients With Relapsed or Refractory Neuroblastoma and Other Solid Tumors

Recruiting
1/2
231
Europe, US, RoW
Topotecan, Hycamtin, Temozolomide, Temodar, Ribociclib, Kisqali, LEE011
Novartis Pharmaceuticals, Innovative Therapies For Children with Cancer Consortium
Neuroblastoma
02/29
02/29
SALA-002-EW16, NCT03600649: Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas

Active, not recruiting
1
50
US
Seclidemstat, LSD1 Inhibitor, SP-2577, Cyclophosphamide, Topotecan
Salarius Pharmaceuticals, LLC, National Pediatric Cancer Foundation
Ewing Sarcoma, Myxoid Liposarcoma, Sarcoma,Soft Tissue, Desmoplastic Small Round Cell Tumor, Extraskeletal Myxoid Chondrosarcoma, Angiomatoid Fibrous Histiocytoma, Clear Cell Sarcoma, Primary Pulmonary Myxoid Sarcoma, Myoepithelial Tumor, Sclerosing Epithelioid Fibrosarcoma, Fibromyxoid Tumor
09/25
12/25
Gantz, Bruce J
NCT04577118: The iotaSOFT Insertion System Safety Study

Completed
N/A
25
US
iotaSOFT Insertion System
iotaMotion, Inc.
Cochlear Implant
04/21
04/21
NCT04750642: Cochlear Implant With Dexamethasone Eluting Electrode Array

Active, not recruiting
N/A
120
US, RoW
CI632D, CI632
Cochlear, NAMSA, Avania, Vanderbilt University
Sensorineural Hearing Loss, Bilateral Hearing Loss
02/24
02/24
NCT06106373: iotaSOFT Pediatric Study

Recruiting
N/A
20
US
iotaSOFT Insertion System
iotaMotion, Inc.
Hearing Loss, Sensorineural, Hearing Loss, Bilateral, Hearing Loss, Unilateral
09/24
12/24
ACE, NCT06664697: Post-Market Clinical Investigation of the IotaSOFT Insertion System

Recruiting
N/A
50
US
Cochlear Implantation with Robotic-Assisted Insertion System
iotaMotion, Inc.
Hearing Loss, Cochlear, Cochlear Implantation, Hearing Loss, Sensorineural
10/25
12/25
DEE-REX, NCT06598059: Safety and Efficacy of a Drug Eluting Slim Modiolar Electrode Array

Recruiting
N/A
56
US
Cochlear implant, CI632D, Slim modiolar dexamethasone-eluting electrode array, Dexamethasone
Cochlear, University of Iowa
Hearing Loss
10/25
08/26
Muscal, Jodi
CAMPFIRE, NCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Recruiting
2
105
Europe, Japan, US, RoW
Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine, Gemcitabine, LY188011, Docetaxel, Abemaciclib, LY2835219, Irinotecan, Temozolomide
Eli Lilly and Company
Neoplasms, Child, Adolescent
05/27
05/27
NCT03654716: Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer

Completed
1
21
US
ALRN-6924, Cytarabine, Cytosar
Dana-Farber Cancer Institute, TeamConnor Childhood Cancer Foundation, Cookies for Kids' Cancer, Aileron Therapeutics, Inc.
Leukemia, Brain Tumor, Solid Tumor, Lymphoma
07/23
07/23
Baxter, Patricia
NCT06161974: Study of Olutasidenib and Temozolomide in HGG

Not yet recruiting
2
60
Europe, Canada, US, RoW
Olutasidenib + TMZ
Rigel Pharmaceuticals, Nationwide Children's Hospital
High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV, Diffuse Intrinsic Pontine Glioma, WHO Grade III Glioma, WHO Grade IV Glioma, Metastatic Brain Tumor, Diffuse Midline Glioma, H3 K27M-Mutant, Thalamus Tumor, Spinal Tumor, IDH1 Mutation, IDH1 R132, IDH1 R132C, IDH1 R132H, IDH1 R132S, IDH1 R132G, IDH1 R132L, Oligodendroglioma
06/29
06/35
PNOC029, NCT05465174: Nivolumab and Tovorafenib for Treatment of Craniopharyngioma in Children and Young Adults

Recruiting
2
56
US
Nivolumab, Opdivo, Tovorafenib, DAY101, TAK580, AMG-2112819, BSK1369
Sabine Mueller, MD, PhD, Bristol-Myers Squibb, Day One Biopharmaceuticals, Inc.
Craniopharyngioma, Child, Craniopharyngioma, Recurrent Craniopharyngioma
03/27
03/28
NCT05843253: Study of Ribociclib and Everolimus in HGG and DIPG

Recruiting
2
100
Europe, Canada, US, RoW
Ribociclib, Kisqali, Everolimus, Afinitor
Nationwide Children's Hospital, Novartis
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma, Glioblastoma Multiforme, Diffuse Midline Glioma, H3 K27M-Mutant, Metastatic Brain Tumor, WHO Grade III Glioma, WHO Grade IV Glioma
08/28
08/34
NCT03904862: Testing the Safety and Tolerability of CX-4945 in Patients With Recurrent Medulloblastoma Who May or May Not Have Surgery

Recruiting
1/2
66
US
CX 4945, Silmitasertib sodium
Pediatric Brain Tumor Consortium, Senhwa Biosciences, Inc., National Cancer Institute (NCI), St. Jude Children's Research Hospital, National Cancer Institute/NIH/DHHS (NCI)
Medulloblastoma, Childhood, Medulloblastoma Recurrent, Medulloblastoma
12/29
02/30
NCT03605550: A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma

Active, not recruiting
1
64
US
PTC596, Radiotherapy
Nationwide Children's Hospital, PTC Therapeutics
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
03/24
03/29
NCT06333899: Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

Not yet recruiting
1
15
Europe, Canada, US, RoW
Lorlatinib, LOBRENA, Lorlatinib with chemotherapy1, Lorlatinib with chemotherapy 2, Lorlatinib post Radiation
Nationwide Children's Hospital, Pfizer
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Infant Type Hemispheric Glioma, Glioblastoma, Glioblastoma Multiforme, WHO Grade III Glioma, WHO Grade IV Glioma, Diffuse Midline Glioma, H3K27-altered
09/27
09/34
NCT04485559: Trametinib and Everolimus for Treatment of Pediatric and Young Adult Patients With Recurrent Gliomas (PNOC021)

Recruiting
1
50
US
Everolimus, 42-O-(2-Hydroxy)ethyl Rapamycin, Afinitor, Certican, RAD 001, RAD001, Votubia, Zortress, Trametinib, GSK1120212, JTP-74057, MEK Inhibitor GSK1120212, Mekinist
University of California, San Francisco, Novartis Pharmaceuticals, Pediatric Brain Tumor Foundation, The Lilabean Foundation for Pediatric Brain Cancer Research
Recurrent World Health Organization (WHO) Grade II Glioma, Low-grade Glioma, High Grade Glioma
12/27
12/27
NCT03033992: Optune for Children With High-Grade Glioma or Ependymoma, and Optune With Radiation Therapy for Children With DIPG

Recruiting
N/A
80
US
Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields), Optune System (NovoTTF-200A System), Concurrent Optune and RT followed by Optune System alone
Pediatric Brain Tumor Consortium, National Cancer Institute (NCI), NovoCure Ltd., American Lebanese Syrian Associated Charities (ALSAC)
Malignant Glioma, Ependymoma, Diffuse Intrinsic Pontine Glioma
07/32
09/32
Sherr, Jennifer
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D)

Recruiting
2
78
US
Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer
Diabetes Mellitus, Type 1
06/26
06/27
NCT05714059: Safety and Effectiveness of the MiniMed™ 780G System With DS5 CGM

Completed
N/A
250
US
Insulin Pump with Continuous Glucose Monitoring
Medtronic Diabetes
Type 1 Diabetes
12/23
12/23
SUCCEED2, NCT06604871: Safety Evaluation of MiniMed™ 780G System with DS5 CGM in Children

Recruiting
N/A
60
US
Insulin Pump with Continuous Glucose Monitoring
Medtronic Diabetes
Type 1 Diabetes
06/25
06/25
Foster, Jennifer H
OPTIMUM, NCT03561259: A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects

Recruiting
2
60
US
131I-MIBG, I-131 meta-iodobenzylguanidine, Iobenguane I-131 MIBG Injection, 131-MIBG + Vorinostat
Jubilant DraxImage Inc.
Neuroblastoma, Neuroectodermal Tumors, Neoplasms
12/23
04/25
NETTER-P, NCT04711135 / 2020-002951-39: Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

Active, not recruiting
2
11
Europe, US
Lutetium [177Lu] oxodotreotide/dotatate, Lutathera
Advanced Accelerator Applications
Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma
03/24
05/29
NCT04901702 / 2021-003570-31: Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Active, not recruiting
1/2
46
Canada, US
Onivyde, Nanoliposomal irinotecan, Talazoparib, BMN 673, Talzenna, Temozolomide, Temodar, Temodal
St. Jude Children's Research Hospital, Pfizer, Ipsen
Recurrent Solid Tumor, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Malignant Germ Cell Tumor, Recurrent Malignant Solid Neoplasm, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Wilms Tumor, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Neoplasm, Refractory Neuroblastoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Soft Tissue Sarcoma
12/25
12/25
NCT03478462: Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma

Active, not recruiting
1
30
Canada, US, RoW
CLR 131, I-131-CLR1404
Cellectar Biosciences, Inc.
Pediatric Solid Tumor, Pediatric Lymphoma, Pediatric Brain Tumor, DIPG, Neuroblastoma, Ewing Sarcoma, Rhabdomyosarcoma, Osteosarcoma
09/22
12/24
NCT04239092: 9-ING-41 in Pediatric Patients with Refractory Malignancies.

Recruiting
1
68
US
9-ING-41, 9-ING-41 COMPOUND, Irinotecan, CPT-11, Temozolomide, Temodar, Cyclophosphamide, Cyclophosphamide IV, Topotecan, Topotecan IV
Actuate Therapeutics Inc.
Refractory Cancer, Refractory Neoplasm, Cancer Pediatric, Refractory Tumor, Pediatric Cancer, Pediatric Brain Tumor, Neuroblastoma, Neuroblastoma Recurrent, Pediatric Lymphoma, Pediatric Meningioma, Diffuse Intrinsic Pontine Glioma
12/24
12/24
NCT05610891: Novel Targeted Radiotherapy in Pediatric Patients With Inoperable Relapsed or Refractory HGG

Recruiting
1
50
Canada, US
CLR 131, iopofosine I 131
Cellectar Biosciences, Inc., National Cancer Institute (NCI)
High-Grade Glioma
05/26
09/26
NCT01590680: Expanded Access Protocol Using 131I-MIBG

Available
N/A
US
I-131 MIBG, I-131 Iobenguane, I-131 meta-iodobenzylguanidine
Jubilant DraxImage Inc.
Neuroblastoma, Pheochromocytoma, Paraganglioma
 
 
Naik, Swati
NCT05305040: Study of Posoleucel (ALVR105,Viralym-M) for Multi-Virus Prevention in Patients Post-Allogeneic Hematopoietic Cell Transplant

Terminated
2/3
451
Europe, Canada, US, RoW
Posoleucel (ALVR105), Viralym-M, Placebo
AlloVir
Adenovirus Infection, BK Virus Infection, Cytomegalovirus Infections, Epstein-Barr Virus Infections, Human Herpes Virus-6 Infection, JC Virus Infection
01/24
01/24
Weiner, Howard
MANIFEST-2, NCT04603495 / 2020-001989-10: Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF)

Jan 2024 - Dec 2024: Approval for myelofibrosis
Hourglass Jul 2024 - Dec 2024 : Regulatory submission in EU for 1L myelofibrosis
Jan 2024 - Mar 2024: From MANIFEST-2 trial in combination with ruxolitinib as a first-line treatment for patients with myelofibrosis
Feb 2024 - Feb 2024: Completion of P2b trial for JIA
Feb 2024 - Feb 2024: Exclusivity expiry in US
Active, not recruiting
3
430
Europe, Canada, US, RoW
Pelabresib, Ruxolitinib, Placebo
Constellation Pharmaceuticals
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
08/23
12/27
SL03-OHD-104, NCT05275439: Phase 1 Study of Shattuck Labs (SL)-172154 in Subjects with MDS or AML

Active, not recruiting
1
160
Europe, Canada, US
SL-172154, Azacitidine, Venetoclax
Shattuck Labs, Inc.
Acute Myeloid Leukemia, Myelodysplastic Syndromes
11/24
11/24
LEE, TIMOTHY C
LeAAPS, NCT05478304: Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial

Recruiting
N/A
6500
Europe, Canada, US
AtriClip LAA Exclusion System
AtriCure, Inc., Population Health Research Institute
Ischemic Stroke, Systemic Embolism
12/31
04/32
Slotkin, Emily
NCT04022213: A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum

Recruiting
2
55
US
131 I-omburtamab, WAP-IMRT, Intensity Modulated Radiation Therapy
Memorial Sloan Kettering Cancer Center, Y-mAbs Therapeutics
Desmoplastic Small Round Cell Tumor, Peritoneal Cancer, Peritoneal Carcinoma
07/25
07/25
NCT02502786: Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma

Active, not recruiting
2
46
US
humanized anti-GD2 antibody, hu3F8, GM-CSF
Memorial Sloan Kettering Cancer Center, Children's Hospital Los Angeles, M.D. Anderson Cancer Center, Y-mAbs Therapeutics
Recurrent Osteosarcoma
07/25
07/25
CAMPFIRE, NCT05999994: A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer

Recruiting
2
105
Europe, Japan, US, RoW
Ramucirumab, LY3009806, Cyclophosphamide, Vinorelbine, Gemcitabine, LY188011, Docetaxel, Abemaciclib, LY2835219, Irinotecan, Temozolomide
Eli Lilly and Company
Neoplasms, Child, Adolescent
05/27
05/27
NCT05130255: GD2-SADA:177Lu-DOTA Complex in Patients With Solid Tumors Known to Express GD2

Recruiting
1
60
US
GD2-SADA:177Lu-DOTA Complex, two-step radioimmunotherapy
Y-mAbs Therapeutics
SCLC, Malignant Melanoma, Sarcoma, High Risk Neuroblastoma
03/27
04/27
NCT01189643: Irinotecan, Temozolomide and Bevacizumab in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Newly Diagnosed Patients With Desmoplastic Small Round Cell Tumor

Active, not recruiting
1
15
US
irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
Memorial Sloan Kettering Cancer Center, Genentech, Inc.
Sarcoma, Desmoplastic Small Round Cell Tumor (DSRCT)
08/25
08/25
NCT03715933: Phase 1 Study of INBRX-109 in Subjects with Locally Advanced or Metastatic Solid Tumors Including Sarcomas

Recruiting
1
321
Europe, US
INBRX-109, Carboplatin, Cisplatin, Pemetrexed, 5-fluorouracil, Irinotecan, Temozolomide
Inhibrx Biosciences, Inc
Colorectal Adenocarcinoma, Ewing Sarcoma
06/26
12/26
Iacobas, Ionela
EPIK-L1, NCT05948943: Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

Recruiting
2/3
230
Europe, US, RoW
Alpelisib, BYL719, Placebo
Novartis Pharmaceuticals
Lymphatic Malformations
10/27
05/30
EPIK-P2, NCT04589650 / 2020-000561-16: Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum

Recruiting
2
205
Europe, Canada, US, RoW
Alpelisib, Placebo
Novartis Pharmaceuticals
PIK3CA-related Overgrowth Spectrum (PROS)
03/24
04/31
Lehman, Heather
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy

Active, not recruiting
3
165
Europe, Canada, Japan, US, RoW
Ligelizumab 120 mg, Ligelizumab 240 mg
Novartis Pharmaceuticals
Food Allergy
02/25
02/25
NCT03878069: Registry Study of Revcovi Treatment in Patients With ADA-SCID

Completed
N/A
32
US
elapegademase-lvlr, Revcovi
Chiesi Farmaceutici S.p.A.
Adenosine Deaminase Severe Combined Immunodeficiency
01/23
01/23
TARGET-DERM, NCT03661866: A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC

Recruiting
N/A
15000
Europe, Canada, US
Target PharmaSolutions, Inc.
Atopic Dermatitis, Alopecia Areata, Hidradenitis Suppurativa, Vitiligo, Psoriasis, Chronic Spontaneous Urticaria
12/50
12/50
Karam, Lina Boujaoude
AMAY, NCT05509777 / 2022-000811-29: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

Recruiting
3
90
Europe, Canada, Japan, US, RoW
Mirikizumab, LY3074828
Eli Lilly and Company, Eli Lilly and Company
Crohn's Disease
07/27
10/27
Fetzko, Stephanie
LIBRETTO-121, NCT03899792 / 2019-000212-28: A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors

Recruiting
1/2
50
Europe, Canada, Japan, US, RoW
LOXO-292, Selpercatinib, LY3527723
Loxo Oncology, Inc., Eli Lilly and Company
Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer, Soft Tissue Sarcoma
12/24
05/29
PIRATE, NCT04525014: RRx-001 Given With Irinotecan and Temozolomide for Pediatric Patients With Recurrent or Progressive Malignant Solid and Central Nervous System Tumors

Terminated
1
2
US
RRx-001, Temozolomide, Irinotecan
EpicentRx, Inc., Texas Children's Cancer Center
Brain Tumor, Recurrent, Brain Tumor, Pediatric, Central Nervous System Neoplasms, Unspecified Childhood Solid Tumor, Protocol Specific
07/24
07/24
Hassanieh, Ghinwa Al
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy

Active, not recruiting
3
165
Europe, Canada, Japan, US, RoW
Ligelizumab 120 mg, Ligelizumab 240 mg
Novartis Pharmaceuticals
Food Allergy
02/25
02/25
Haines, Keri
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy

Active, not recruiting
3
165
Europe, Canada, Japan, US, RoW
Ligelizumab 120 mg, Ligelizumab 240 mg
Novartis Pharmaceuticals
Food Allergy
02/25
02/25
NCT05432388 / 2021-006950-30: Study of Efficacy, Safety and Tolerability of Remibrutinib in Adult Participants With an Allergy to Peanuts

Recruiting
2
72
Europe, US
remibrutinib, (LOU064), placebo
Novartis Pharmaceuticals, Novartis Pharma AG
Allergy, Peanut
03/25
03/25
ad, Amal Assa
NCT05678959: Long-term Extension Study of Ligelizumab in Food Allergy

Active, not recruiting
3
165
Europe, Canada, Japan, US, RoW
Ligelizumab 120 mg, Ligelizumab 240 mg
Novartis Pharmaceuticals
Food Allergy
02/25
02/25

Download Options